evans blue has been researched along with docetaxel anhydrous in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bougnoux, P; Champeroux, P; Chevalier, S; Goupille, C; Kornfeld, S; Lebeau, J; Mahéo, K; Martel, E; Maurin, A; Pinet, A; Richard, S; Tranquart, F; Vibet, S | 1 |
1 other study(ies) available for evans blue and docetaxel anhydrous
Article | Year |
---|---|
Reducing endothelial NOS activation and interstitial fluid pressure with n-3 PUFA offset tumor chemoresistance.
Topics: Animals; Cell Movement; Cells, Cultured; Coloring Agents; Disease Progression; Docetaxel; Docosahexaenoic Acids; Drug Resistance, Neoplasm; Eicosapentaenoic Acid; Endothelial Cells; Evans Blue; Extracellular Fluid; Fatty Acids, Omega-3; Female; Human Umbilical Vein Endothelial Cells; Humans; Mammary Neoplasms, Animal; Neoplasm Metastasis; Neovascularization, Physiologic; Nitric Oxide Synthase Type III; Permeability; Phosphorylation; Rats; Rats, Sprague-Dawley; Signal Transduction; Taxoids; Vascular Endothelial Growth Factor A | 2012 |